PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629315
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629315
Embolotherapy Market size was valued at US$ 4,115.2 Million in 2024, expanding at a CAGR of 8.60% from 2025 to 2032.
Embolotherapy is the practice of treating or halting uncontrollable bleeding by blocking arteries with a device (such as a balloon catheter). By using this method, bleeding is managed, and tumours are decreased. By limiting abnormal blood vessels, this endovascular technique aims to halt bleeding. Postpartum conditions, pelvic tract bleeding, and cervical uprooted pregnancy are the main conditions treated with embolotherapy. Lesions to the liver, spleen, and kidneys are among the vascular, non-operative, and iatrogenic solid organ damage that this treatment has demonstrated potential to treat. Embolotherapy is used to remove duodenal varices, revascularize tissues and organs before surgery, and treat enlarged uterine fibroids. Selecting an embolization agent with the required degree of vascular blockage persistence is therefore required. The need for embolotherapy will expand due to the growing prevalence of liver and hepatic cancers, as well as the top manufacturers' heightened focus on technological advancements. Additionally, increased infrastructure construction expenses and better research & development skills to promote healthcare technology will drive growth in the embolotherapy market. Growing patient demand for minimally invasive procedures and increased personal disposable income are other factors driving market expansion.
Embolotherapy Market- Market Dynamics
Increase in target procedures due to the expanding target patient pool
The market for embolotherapy devices has grown steadily over the past ten years as a result of an increase in target procedures due to the expanding target patient pool. CVD is a major target illness, and because of its significance and high incidence, research on successful and efficient treatments has focused on it. Globally, more than 200 million people had peripheral vascular disorders as of 2017. The same source claims that the prevalence of these illnesses increases with age, with a prevalence rate of more than 20% seen in the over-80 age range. Moreover, The increasing prevalence of hepatocellular and liver cancers, along with the high success rate and low rate of post-operative complications linked to embolotherapy treatments, will increase the need for embolotherapy devices in the near future. The ninth most prevalent cancer in women and the fifth most common in men is liver cancer. More than 840,000 new cases were diagnosed worldwide in 2018. In addition, the UK had a 42% increase in kidney cancer incidence rates during the previous ten years. There was a 38% incidence rate in males and a 44% increase rate in females.
Embolotherapy Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.60% over the forecast period (2025-2032)
Based on product segmentation, the embolic agents were predicted to show maximum market share in the year 2024
Based on end use segmentation, hospitals and clinics were the leading segment in 2024
Based on procedure segmentation, Transcatheter Arterial Embolization was the leading segment in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Embolotherapy Market is segmented on the basis of Product, Application, End Use, Procedure, and Region.
On the basis of product, the market is segregated into Embolization Coil (Pushable Coils, Detachable Coils), Detachable Balloons, Embolic Agents (Microspheres, Liquid Embolic Agents), Embolic Plug Systems, and Support Devices (Microcatheters, Guidewires). The market for embolotherapy is dominated by embolic agents in 2024. For the most part, this segment dominates the market because of the growing usage of embolic agents in several interventional radiological treatments. Additionally, the category is anticipated to grow at the fastest rate during the forecast period due to the developments in such agents, such as drug-eluting microspheres, calibrated microspheres for bland embolization, and radioactive yttrium-90 microspheres for primary or secondary liver diseases. Since microspheres are frequently employed to treat HCC, their increasing use directly contributes to the demand for them. The American Cancer Society reports that about 850,000 liver cancer diagnoses are made worldwide each year. Moreover, another important factor propelling this category is the continuous study of creating multipurpose and biodegradable microspheres. By combining chemotherapeutic drugs with therapeutic radionuclides, these microspheres can provide an efficient treatment for HCC.
Based on end use, the market is divided into Hospitals and Clinics, Ambulatory Surgical Centers (ASCs), and Others. In 2024, the hospitals and clinics category held a dominant market share. The primary end consumers of embolic agents and embolotherapy equipment are critical care units, minor clinics, and large hospitals. At these locations, the number of embolotherapy procedures is being driven by the growing use of minimally invasive surgical procedures, such as vascular, neurological, and urological interventions. For embolization operations, facilities with established infrastructure that facilitates all-encompassing patient care-such as interventional radiology departments-are favoured. There is a greater need for embolotherapy equipment and embolic agents in hospitals because they have more patients than ambulatory surgery centres. The expansion of this category is also fueled by the larger healthcare providers' growing purchasing power and the availability of reimbursement for embolotherapy procedures in the United States and other significant European markets.
Embolotherapy Market- Geographical Insights
In 2024, North America held the largest market share for embolotherapy because of its highly developed and advanced healthcare infrastructure, which includes specialist centres with the newest embolotherapy technology, interventional radiology departments, and state-of-the-art medical facilities. Particularly in the United States, healthcare spending is among the highest in the world. In addition to facilitating the adoption of cutting-edge technologies, the substantial investment in healthcare resources makes modern medical procedures, such as embolotherapy, widely accessible. The healthcare workforce in North America is highly qualified and experienced and includes specialized nursing personnel and interventional radiologists. The effective implementation and growth of embolotherapy treatments depend on the availability of skilled personnel. The area is also at the forefront of technical advancement and medical research.
The Asia-Pacific region is anticipated to account for a sizeable portion of the market. In Asia-Pacific nations, chronic illnesses like cancer, peripheral vascular disease, and neurological disorders are on the rise. The region's need for embolization tools and procedures is rising as a result of these situations being perfect candidates for embolization operations. In Asia Pacific, governments and private healthcare providers are investing more in state-of-the-art medical technology and healthcare infrastructure. 50% of all new cancer cases worldwide occur in Asia Pacific, and by 2030, the number of cancer-related fatalities in Asia is predicted to rise by 36%. In 2024, the World Economic Forum anticipated that 58% of cervical cancer fatalities and 45% of all breast cancer diagnoses globally occur in Asia. Therefore, it is anticipated that the elements above will maintain the region's leading position.
Key players in the embolotherapy market include Terumo Corporation, Merit Medical Systems, Inc., Simbionix USA Corporation, Cook, Boston Scientific Corporation, Penumbra, Inc., Meril Life Sciences Pvt. Ltd., Medtronic, and others. The market's companies have been concentrating on innovations. Offering more effective solutions in response to changing end-user needs is a major focus. The market for embolotherapy is thought to be fairly fragmented because of the large number of players. In addition, industry participants have made partnerships a crucial tactic in their efforts to broaden both their product offerings and their geographical presence. For instance, in December 2023, the innovative AZUR HydroPack Peripheral Coil System from Terumo Medical Corporation was introduced in the US. A platinum and hydrogel coil with a flexible, universal shape, the AZUR HydroPack Coil System is made to locate and fill space inside the vessel.
Recent Development
June 2024: Boston Scientific Corporation announced plans to buy Silk Road Medical Inc., a medical device firm based in Silicon Valley. Through a minimally invasive treatment called trans carotid artery revascularization, the latter provides products to help patients with carotid artery disease avoid strokes.
February 2024: Leading French medical imaging AI specialist AI announced a strategic partnership to integrate its CE-marked CINA-iPE solution into the Blackford AI Platform. This collaboration gives medical professionals cutting-edge resources to detect incidental pulmonary embolisms during standard CT scans more accurately.
September 2023: Magle Group, a Swedish CDMO and vendor of degradable starch microspheres, and Sirtex Medical announced an exclusive global distribution deal. Sirtex Medical exclusively distributes the EmboCept S DSM 50 μm chemoembolization product from Magle Group in both new and existing markets as part of the collaboration.